Sotera Health Company provides specialized services in the field of sterilization, microbial reduction, and lab testing, primarily for the healthcare and pharmaceutical industries. The company offers comprehensive solutions to ensure the safety and efficacy of medical devices, pharmaceuticals, and other critical products through advanced sterilization processes, such as ethylene oxide gas and radiation treatments. In addition, Sotera Health focuses on compliance and regulatory support to help clients meet stringent industry standards, ultimately contributing to patient safety and overall public health. Their broad range of services is designed to enhance product quality and facilitate market access for their clients. Read More
Healthcare services company Sotera Health (NASDAQ:) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 6.4% year on year to $294.3 million. Its non-GAAP profit of $0.20 per share was 15.9% above analysts’ consensus estimates.
CLEVELAND, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three- and six- months ended June 30, 2025.
CLEVELAND, July 28, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the second-quarter ended June 30, 2025 before the market opens on Friday, August 8, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company’s financial results and operating highlights.
Looking back on research tools & consumables stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Danaher (NYSE:DHR) and its peers.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how research tools & consumables stocks fared in Q1, starting with Sotera Health Company (NASDAQ:SHC).
Healthcare services company Sotera Health (NASDAQ:) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.6% year on year to $254.5 million. Its non-GAAP profit of $0.14 per share was 14.9% above analysts’ consensus estimates.
CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three months ended March 31, 2025.
CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the first-quarter ended March 31, 2025 before the market opens on Thursday, May 1, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company’s financial results and operating highlights.
Shareholders of Sotera Health Company would probably like to forget the past six months even happened. The stock dropped 28.2% and now trades at $11.07. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Let’s dig into the relative performance of Avantor (NYSE:AVTR) and its peers as we unravel the now-completed Q4 research tools & consumables earnings season.
Let’s dig into the relative performance of Bio-Techne (NASDAQ:TECH) and its peers as we unravel the now-completed Q4 research tools & consumables earnings season.
Looking back on research tools & consumables stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Sotera Health Company (NASDAQ:SHC) and its peers.
Rapid Sterility Testing yields product sterility test results in as little as 6 days and can be used for broadscale medical device and pharmaceutical product application
Healthcare services company Sotera Health (NASDAQ:) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 6.5% year on year to $290.2 million. Its non-GAAP profit of $0.21 per share was in line with analysts’ consensus estimates.
CLEVELAND, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the fourth-quarter and full-year 2024 and its initial 2025 outlook.
